MHRA Limits Nasal Decongestant Sprays to Five Days to Prevent Rebound Congestion

The familiar ritual of reaching for a nasal spray when blocked sinuses strike has just become more restricted. The Medicines and Healthcare products Regulatory Agency has announced new limits on popular decongestant sprays, cutting maximum use from seven days to just five.

The Science Behind the Change

The decision affects over-the-counter sprays containing xylometazoline and oxymetazoline – ingredients found in many household medicine cabinets across Kent. These treatments help adults and children aged 12 and above tackle nasal congestion from colds, flu, allergies, sinusitis, and allergic rhinitis.

But there’s a catch that many users don’t realise. Excessive use can trigger rebound congestion, creating a vicious cycle where the remedy becomes the problem.

This condition, known as rhinitis medicamentosa, brings chronic nasal congestion and tissue damage. The nose becomes dependent on the spray, requiring increasingly frequent doses just to breathe normally.

What’s Changing on the Shelves

New packaging and patient leaflets will clearly state the five-day limit and strengthen warnings about overuse. However, the transition won’t happen overnight – it could take months for updated packaging to reach pharmacy shelves.

Existing stock may still display the old seven-day guidance, potentially confusing customers who’ve been using these products for years.

The MHRA’s advice is clear: follow the five-day limit immediately, even if your current spray shows different instructions. If symptoms persist beyond this period, it’s time to seek alternatives rather than continue spraying.

Professional Backing

The update follows recommendations from the Cardiovascular, Respiratory, Renal and Allergy Expert Advisory Group and Pharmacovigilance Expert Advisory Group to the Commission on Human Medicines. These bodies reviewed evidence of side effects from prolonged use.

NICE guidance already recommends intranasal corticosteroids and antihistamines as first-line treatments for allergic rhinitis, with decongestants reserved for short-term use when other options haven’t worked.

Healthcare professionals and pharmacists have welcomed the clearer guidance, which should help them advise patients more effectively about safe usage patterns.

Key Takeaways

• Nasal sprays with xylometazoline and oxymetazoline now limited to five days maximum use
• Prolonged use can cause rebound congestion and chronic nasal problems
• New packaging will reflect changes, but existing products may still show seven-day limits

What This Means for Kent Residents

Kent residents currently using these nasal sprays should immediately switch to the five-day limit, regardless of what their current packaging states. If congestion persists beyond five days, contact your local GP practice through NHS 111 or visit a pharmacy under NHS Kent and Medway Integrated Care Board for alternative treatments. Avoid combining these sprays with other sympathomimetic decongestants, and remember that persistent nasal symptoms may require different approaches than quick-fix decongestant sprays.